About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Indoco Remedies Ltd.
Change Company
BSE Code
532612
ISIN Demat
INE873D01024
Book Value
115.96
NSE Code
INDOCO
Dividend Yield %
0.10
Market Cap
19379.14
P/E
0.00
EPS
-6.42
Face Value
2
1 Week
1 Month
3 Months
6 Months
1 Year
14-Apr-2026
USFDA concludes inspection of Indoco Remedies’ te...
24-Feb-2026
Indoco Remedies secures final ANDA approval for B...
24-Feb-2026
Indoco Remedies jumps on securing final ANDA appr...
03-Feb-2026
Indoco Remedies informs about allotment of ESOP
30-Jan-2026
Indoco Remedies gets nod for Lacosamide Oral Solu...
30-Jan-2026
Indoco Remedies informs about press release
19-Dec-2025
Indoco Remedies informs about disclosure
12-Dec-2025
Indoco Remedies gets EIR from USFDA for API manuf...
12-Dec-2025
Indoco Remedies rises on getting EIR from USFDA f...
07-Nov-2025
Indoco Remedies informs about newspaper publicati...
06-Nov-2025
Indoco Remedies informs about board meeting outco...
18-Oct-2025
Indoco Remedies informs about newspaper publicati...
14-Oct-2025
Indoco Remedies submits board meeting intimation
19-Sep-2025
USFDA completes inspection at Indoco Remedies’ AP...
19-Sep-2025
Indoco Remedies informs about investors meet
Page
1
of
2
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Smart ODR Portal
|
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
|
UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.